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Objectives: Infusions of aminobisphonates (ABP) activate Vγ9δ2T cells in vivo and induce
an acute inflammatory response in 30% of patients treated for osteoporosis. Following the
observation of digital thrombosis in a systemic sclerosis (SSc) patient after treatment with
an intravenous ABP, zoledronate (Zol), we evaluated whether patient and control peripheral
blood (PB) mononuclear cell (MC, PBMC) acquire a prothrombotic phenotype in response
to Zol.
Results: Vγ9δ2T cells of both patients and healthy donors (HD) upregulated the CD69 acti-
vation antigen and secreted tumor necrosis factor (TNF)α in response to Zol in vitro. In
addition, exposure to either Zol or lipopolysaccharide (LPS), or to both additively, induced
expression of the highly procoagulant, tissue factor (TF)-1 on CD14+ monocytes. Impor-
tantly, only Zol-induced TF-1 was blocked by a monoclonal antibody to TNFα. Interestingly,
we found that SSc, but not HD, Vδ1+T cells were concurrently activated by Zol to produce
interleukin (IL)-4. Addition of plasma from the blood of the SSc patient who developed
critical digital ischemia after infusion of Zol, but neither plasma from a second patient with
no adverse clinical response to Zol infusion nor of a HD, strongly enhanced Zol-induced
monocyte TF-1, which could still be blocked by anti-TNFα.
Conclusion: Aminobisphonates induced secretion of TNFα by Vγ9δ2+T cells may lead to
TNFα-dependent induction of procoagulant TF-1 induction on monocytes. In certain clini-
cal settings, e.g., SSc, TF-1+ monocytes could play a role in triggering clinically relevant
thrombosis.
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INTRODUCTION
γδ T cells are a subset of T cells combining innate and adaptive
functions (1). In Caucasians, 50% of the circulating γδ T cells
express the γ9 and δ2 genes in the Variable (V) region of the
γδ T cell receptor (TCR) Vγ9δ2 T cells (2). Vγ9δ2 TCR recog-
nize metabolites produced in the classical (isopentenyl pyrophos-
phate, IPP) and alternative [(E)-4-hydroxy-3-methyl-but-2-enyl
pyrophosphate (HMBPP)] mevalonate metabolic pathways. These
antigens are presented for TCR-mediated recognition by CD277,
a ubiquitously expressed cell surface membrane antigen pre-
senting molecule (APM) (3). Together with co-stimulatory sig-
nals delivered by antigen presenting cells (APC), Vγ9δ2 TCR–
CD277/IPP cognitive interactions activate the Vγ9δ2 T cells to
secrete cytokines and exert cytotoxic effects. A second major sub-
set of γδ T cells expresses the Vδ1 gene in the TCR structure,
among which a major portion recognize phospholipid antigens
(e.g., sulfatide) presented by CD1 family molecules (4).
Vδ1 γδ T cells have been shown to expand oligoclonally in the
PB of certain systemic sclerosis (SSc) patients, infiltrate the skin
in early phases of the disease, and may secrete factors enhanc-
ing collagen production (5). Vγ9δ2 T cells are also functional
in SSc patients, since their circulating Vγ9δ2 T cells secrete
tumor necrosis factor (TNF)α and IFNγ and induce fibroblast
apoptosis in the presence of exogenously added IPP (6). How-
ever, the immunopathogenic significance of these cells concern-
ing the clinical manifestations in SSc patients remains largely
unknown.
In this regard, interactions of γδ T cells with bisphosphonate-
activated CD14+monocytes may play a critical role. Bisphospho-
nates block farnesylpyrophosphate synthase (FPPS) downstream
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of IPP in the mevalonate pathway in circulating CD14+ mono-
cytes, increasing intracellular IPP, which is presented to circulating
Vγ9δ2 T cells leading to their activation (7, 8). As a consequence,
these cells produce TNFα and IFNγ, the central mediators of the
acute phase response (APR) following infusion of zoledronate
(Zol) to patients (8). Accordingly, upon administration of a bis-
phosphonate drug for osteoporosis or to decrease bone metastasis
in cancer, an APR characterized by fever, chills, and arthralgia
occurs in up to 30% of patients (8). Zol also activates dendritic
cells and natural killer (NK) cells at least in part dependent upon
Vγ9δ2 T cell activation (9, 10). CD86 and other stimulatory mol-
ecules, which enhance activation of other T cell subsets are also
upregulated by Zol on dendritic cells (11). Recently, Zol was also
shown to stimulate B cells directly (12). Our recent observation of
the rapid onset of gangrene of fingers and toes in a patient with SSc
after Zol administration prompted the experiments in this study
that were designed to evaluate how bisphosphonate-activated γδ
T cells could play a pathogenic role in SSc.
MATERIALS AND METHODS
PATIENTS
The study was approved by the Institutional Review Board
(Helsinki Committee) of the Sheba Medical Center, Ramat Gan,
Israel. All patients participating in the study were seen in the
Rheumatology and Pulmonary clinics at Sheba or Rambam med-
ical centers. Patients fulfilled the criteria of the American College of
Rheumatology for systemic sclerosis (SSc), also named herein scle-
roderma (SCL) (13). Controls included six healthy donors (HD),
two patients with idiopathic pulmonary fibrosis (IPF), and one
patient with polymyalgia rheumatica (PMR).
ISOLATION OF PBMC AND CHARACTERIZATION OF CELL SUBSETS
PBMC were isolated by Lymphoprep (AXIS-SHIELD, Oslo, Nor-
way) density centrifugation and cultured in growth medium as
previously described (14). Cells were stained with fluorochrome
conjugated monoclonal antibodies (mAb) specific to CD4, CD3,
CD142, CD14, CD69, or isotype control (BD Biosciences), or
to human Vγ9, Vδ2 (Immunotech), and Vδ1 (Endogen, Pierce)
and analyzed by flow cytometry (Calibur, Beckton Dickinson,
CA, USA).
TISSUE FACTOR INDUCTION AND INHIBITION
PBMC were incubated and stimulated either with 2µM of
Zol (Novartis) overnight (ON) or with 50 ng/ml of E. coli
0111:B4 lipopolysaccharide (LPS) (InvivoGen) for 3 h. For dou-
ble LPS+Zol stimulation, cells were cultured with Zol ON then
LPS was added for an additional 3 h. Cells were harvested, washed,
and stained with CD14 and CD142 specific antibodies. For inhi-
bition experiments, PBMC from HD were cultured in medium
with increasing dilutions of either anti-TNFα antibody (Inflix-
imab, Janssen Biologics) or control IgG mix (Gammaplex, Bio
Products Laboratory, Herts, UK) prior to stimulation with Zol
or/and LPS.
CYTOKINE DETECTION
Intracellular cytokine detection was performed as previously
reported (14). IFNγ detection in supernatants was done using
the ELISA max Deluxe Sets (Biolegend, CA, USA) according to the
manufacturer’s instructions.
RESULTS
SSc-DISEASE SPECIFIC RESPONSE OF Vδ1+ T CELLS TO ZOL
Activation of γδ T cells in SSc patients was compared to that of
healthy individuals and patients with other chronic inflamma-
tory diseases quantitating percentage of cells producing a panel
of relevant intracellular cytokines. Thus, PBMC were incubated
ON with Zol and secretion of cytokines was measured by intra-
cellular staining of PB T cell subsets. Percentage of cells among
the CD4+, Vγ9δ2+, and Vδ1+ T cell subsets in PBMC of 3 SSc
patients (RP0-2), 3 non-SSc patients with IPF or PMR (Pt 1–
3), and 6 HD that were induced to secrete IFNγ, TNFα, IL-4,
or IL-9 after 4.5 h of incubation in medium alone, or with Zol
or PMA (20 ng/ml) and ionomycin (0.8µM) (P/I) are shown in
Figure 1. A significantly higher percentage of IL-4 producing cells
was observed among SSc patient’s Vδ1+ cells exposed to Zol com-
pared to either non-SSc patients (p< 0.03, Student T test) or HD
(p< 0.003, Student T test). In contrast, there was no significant
difference in the mean percentage of cells secreting any of the
other cytokines in SSc compared to HD in the remaining T cell
subsets. SSc patient IFNγ production was, however, significantly
lower than in the non-SSc patients among Zol-activated CD4+
T cells, and P/I-activated Vδ1+ T cells. Among SSc Vδ1+ T cells,
the percentage of Zol-activated IL-9 producers were also signif-
icantly lower than in non-SSc patients (p< 0.05). These results
point to a unique pattern of production of cytokines of SSc Vδ1+
γδ T cells in response to Zol, relative to HD and patients with
other chronic inflammatory and fibrotic diseases, characterized
by increased production of IL-4 (relative to both HD and disease
controls), and decreased production of IL-9 relative to the disease
controls.
ACTIVATION OF PATIENT RP2 Vγ9δ2+ T CELLS BY ZOL
During the course of these studies, only one of our SSc patients
(RP2) developed an unusually dramatic APR after receiving intra-
venous Zol. Since TNFα and IFNγ produced by Vγ9δ2 γδ T cells
are thought to be the mediators of the APR and IFNγ was weakly
produced in SSc patients in response to Zol (Figure 1), we exam-
ined in further detail how Zol had affected TNFα production by
this patient’s (RP2) PB T cell subsets. As expected, CD4+, Vγ9δ2
as well as Vδ1+ T cells in PBMC of RP2, RP1, and a healthy blood
donor all increased their intracellular TNFα in response to P/I,
an activating stimulus for T cells that bypasses signals dependent
upon cognitive TCR-antigen interactions. Zol potently induced
RP2 Vγ9δ2 T cells (but not CD4+ or Vδ1+ T cells) to produce
TNFα, similar to its effect on a HD PBMC (Figure 2) whereas
those of RP1 an SSc patient who had received Zol but no clin-
ical APR did not secrete TNFα in response to Zol application
in vitro. Production of TNFα was linked to Zol-dependent activa-
tion of Vγ9δ2+ γδ T cells. Thus, a markedly increased expression
of CD69 on the surface of Vγ9δ2 cells (but not Vδ1+ cells or
CD4+ T cells) was concomitantly noted in the presence of Zol
on RP2 and HD but not on RP1 Vγ9δ2+ T cells. In contrast, P/I
stimulation increased CD69 expression in all T cell subsets in all
individuals tested (except in HD Vδ1+ cells).
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FIGURE 1 | Cytokine expression pattern inT cell subsets in systemic
sclerosis (scleroderma, SSc), control patients, and healthy donors is
shown. Bars represent percent cells in the indicated T cell subsets ±1 SEM
after activation of PBMC from healthy donors (HD) (n=5) or scleroderma
(SSc) patients (n= 3) or non-scleroderma (SSc) control patients (n=3)
following stimulation with Zol, PMA, and ionomycin or medium (Med) (A).
(B) Representative plots show IL-4 secretion by Vδ1+T cells from RP-2, a
control patient, or a HD in response to Zol, PMA+ Ionomycin, or medium.
www.frontiersin.org September 2014 | Volume 5 | Article 414 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marcu-Malina et al. Prothrombotic γδT cells in systemic sclerosis
FIGURE 2 |Vγ9δ2T cells of patient RP2 producedTNFα in response to
zoledronate. Bars represent percent cells of HD10, and of SSc patients RP2
and RP1, within the indicated T cells subsets expressing intracellular TNFα
(A) or surface CD69 (C) after stimulation with medium, Zol or PMA, and
ionomycin. (B) Representative FACS plots of TNFα staining in the
corresponding T cells from patients indicated on the left after Zol stimulation.
Numbers indicate percentages of the particular cell population in the
respective rectangle.
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INDUCTION OF TNFα-DEPENDENT TISSUE FACTOR ON CD14+
MONOCYTES BY ZOL
The occurrence of digital ischemia during the APR in RP2
prompted us to examine whether TNFα produced by Vγ9δ2+
cells in response to Zol is sufficient to induce tissue factor (TF)-
1, a potent procoagulant factor, on the cell surface membrane
of monocytes present in PBMC (15). We utilized HD PBMC to
address this issue, because we could obtain only two PB samples
from patient RP2 and the patient’s response to Zol with respect
to TNFα secretion was similar to that of HD (Figure 2). Thus,
HD PBMC were incubated ON in medium alone or medium
containing Zol. Subsequently, LPS, a known inducer of TF-1 on
monocytes, was added to the medium for an additional 3 h. The
expression of the CD142 antigen, which identifies TF-1 on the
cell surface, was assessed by FACS analysis after gating on CD14+
monocytes. A marked and significant upregulation of CD142 on
HD-derived monocytic CD14+ cells cultured with either Zol
alone ON or after the brief 3 h LPS stimulation was observed
(Figure 3). There was no upregulation of CD14 in these exper-
iments, indicating that upregulation of CD142 was not due to
non-specific elevation of surface membrane molecules on mono-
cytes (data not shown). Furthermore, an additive effect on CD142
levels of expression was noted in PBMC cultured in the presence
of both reagents (Figure 3).
FIGURE 3 | Zoledronate induces tissue factor-1 (TF-1) surface
expression on CD14+ monocytes. (A) Histograms in the second panels
depict TF-1 expression as percent CD142+ among CD14+ monocytes in
PBMC cultured in medium or after stimulation with Zol, LPS, or with
both, as indicated (see Materials and Methods). The panel above shows
forward (FSC) and side scatter (SSC) dot plots of the PBMC gating used
to identify monocytes and expression of CD14 in the gated monocyte
subset. (B) Summary of five independent experiments showing
%CD142+ monocytes in cultures of HD PBMC as above. *p<0.05,
***p<0.0001.
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We next performed similar experiments and included inflix-
imab, a TNFα neutralizing humanized mAb, or similar concentra-
tions of non-specific human IgG, in parallel cultures. Infliximab
abolished, in a dose-dependent manner, induction of TF-1 on the
surface membrane of CD14+ monocytes in response to Zol but
not to LPS (Figure 4). Although control IgG also slightly reduced
TF-1 expression induced by Zol, inhibition was incomplete even
at high concentrations of IgG. Together, these results indicate that
Zol, when added to PBMC, induces TNFα secretion by theVγ9δ2+
T cells in the PBMC and TNFα-dependent expression of TF-1 on
CD14+monocytes.
EFFECT OF PATIENT PLASMA ON TF-1 INDUCTION
Zoledronate has not been previously reported to induce digital
necrosis despite its widespread use in patients. Furthermore, in
our experience, which included four SSc patients, only RP2 devel-
oped an APR and critical digital ischemia, in which TF-1 may have
contributed. It was thus of interest to determine the role of RP2
patient specific factors in the development of the unusual response
to Zol. We found that addition of RP2-plasma (RP2-P) markedly
increased TF-1 induction on CD14+monocytes in response to Zol
as well as LPS, whereas control plasma (RP1-P) from SSc patient
RP1 who had received Zol with no toxic effect did not enhance
TF-1 induction (Figure 5). Importantly, addition of anti-TNFα
mAb but not of non-specific IgG still completely abolished TF-1
upregulation in response to Zol even in the presence of RP2-P.
Anti-TNFα mAb did not reduce TF-1 upregulation in response
to LPS or the combination of LPS and Zol in the presence of
RP2-P. These results suggest that the patient’s plasma specifically
contained factor/s that enhance Zol-induced Vγ9δ2+ produced
TNFα-dependent TF-1 expression on monocytes in vitro, suggest-
ing that a similar effect may have taken place following IV infusion
on her circulating monocytes.
DISCUSSION
This paper shows, for the first time, an SSc specific effect of Zol, i.e.,
the enhancement of IL-4 secretion by PB Vδ1+ T cells, coupled
with diminished ability of these cells to secrete IL-9 relative to two
patients with another form of fibrosing disease, IPF. Furthermore,
Zol induced secretion of TNFα by Vγ9δ2+ T cells from some SSc
patients similar to healthy individuals, which in turn induced TF-
1 on CD14+ monocytes. Finally, plasma of an SSc patient who
suffered a clinically detrimental inflammatory response strongly
augmented this TNFα-dependent TF-1 expression on monocytes.
These data suggest that activation of both major γδ T cell subsets –
Vδ1+ and Vγ9δ2+ by Zol could activate pathogenic mechanisms,
e.g., fibrosis (via IL-4) and thrombosis (via TF-1) – relevant to
clinical manifestations in SSc patients.
The bisphosphonate-induced APR in patients receiving intra-
venous therapy for osteoporosis or cancer differs from a typical
APR. Thus, CD14+monocytes and macrophages are the primary
cytokine producing cells in the latter, whereas bisphosphonates
induce rapid and copious production of TNFα, IFNγ, and IL-6
primarily by PB Vγ9δ2 T cells (16). Activation of the Vγ9δ2+
T cells triggered by upregulation of IPP in monocytes in turn
enhances CD14, CD40, CD80, and HLA-DR on circulating mono-
cytes (8). Zol also enhances TNF-related apoptosis-inducing lig-
and (TRAIL) in γδ T and NK cells, and release of high mobility
group box 1 (HMGB1) from γδ T cells and monocytes (17). Fur-
thermore, soluble factors released by activated Vδ2/monocytes co-
cultures induce granulocyte migration and activation (18). Acti-
vated Vγ9δ2T cells also trigger granulocyte functions via MCP-2
release during bacterial infection (9).
The novel finding shown here, i.e., induction of TF-1 on mono-
cytes, in a manner dependent upon TNFα produced by Vγ9δ2+
T cells stimulated with Zol, adds an additional dimension to the
role of monocyte–Vγ9δ2 interactions, that may play a critical role
in clinical medicine, since TF-1 expressing monocytes play an
important role in thrombotic diseases (19). For example, patients
with cardio- and cerebro-vascular disease have increased TF-1
expression on circulating monocytes and TF-1-positive monocyte-
derived circulating microparticles in the blood (20, 21). Fur-
thermore, circulating monocyte-derived microparticles expressing
TF-1 are associated with acute recurrent deep venous thrombosis
(22). In experimental hypercholesterolemic mice, the associated
prothrombotic state is caused by oxidized low density lipoprotein
FIGURE 4 | Upregulation ofTF-1 in response to Zol isTNFα-dependent.
PBMC from a healthy donor were cultured in medium with graded dilutions
(indicated on the x axis) of either anti-TNFα mAb or control IgG. Cells were
stimulated with Zol, with LPS or not stimulated (medium), and TF-1 was
measured by flow cytometry as described in Figure 3. Results are
representative of three experiments.
Frontiers in Immunology | T Cell Biology September 2014 | Volume 5 | Article 414 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marcu-Malina et al. Prothrombotic γδT cells in systemic sclerosis
FIGURE 5 | RP2-plasma increasesTNFα-dependent upregulation
ofTF-1 in response to LPS and Zol. (A) Bars represent percent±1
SEM of CD14+ cells expressing TF-1 (CD142) in PBMC cultures from
three HDs, cultured with the indicated stimuli on the X axis, in the
presence of medium containing 10% FBS or RP1- or RP2-plasma
(RP1-P or RP2-P). (B) Shows the same experiment done in the
presence of 10µg/ml anti-TNFα antibody or control IgG as
indicated.
engagement of a toll-like receptor (TLR)4/TLR6 complex, lead-
ing to induction of TF-1 in monocytes (23). In addition, in rats,
monocytes in blood vessels of kidneys undergoing acute rejection
express high levels of TF-1 (24). These data suggest that Zol infu-
sion, which achieves concentrations of zoledronate in the plasma
similar to those we have used in our experiments, may lead to
induction of TF-1 on circulating monocytes resulting in a pro-
thrombotic state, which may have contributed to development of
ischemic digits in SSc RP2 patient described here (25). Our data,
furthermore, show that Zol-induced TF-1 on monocytes is at least
partly dependent upon Vγ9δ2 cell produced TNFα (Figures 1
and 5). In contrast, a combination of mAb to TNFα and IL-1β,
but neither alone, was required to inhibit high molecular weight
kininogen induced monocyte TF-1 (26). TNFα may also upregu-
late monocyte TF-1 activity indirectly via its effects on endothelial
cells (27, 28).
Although Zol induced increase of TF-1 on monocytes, overt
thrombosis in the absence of additional factors is rare. Neverthe-
less, inclusion of zoledronic acid in the treatment protocols for
multiple myeloma (MM) and breast cancer significantly increases
venous thrombosis (29–32). In this regard, Vγ9δ2+ T cells may be
playing a role, since in both MM and breast cancer patients, these
cells are known to become activated by Zol (33–36). These data
suggest that Zol-induced thrombosis is dependent upon disease
and/or patient specific factors, which may include Zol responsive
Vγ9δ2+ T cells in the PB and additional factors.
Our data suggest that SSc may constitute a risk for severe
prothrombotic γδ T cell-mediated Zol-induced reactions. In this
regard, the already diseased endothelium in SSc may play a role,
since activated γδ T cells of SSc patients, in particular, adhere to
and damage endothelial cells, creating a substrate for enhancing
thrombosis (37). The current data suggest that at least two addi-
tional factors could play a role in Zol-induced thrombosis in
SSc patients. First, SSc patient’s plasma may contain factors that
enhance TF-1 expression in response to Zol [Figure 5 and Ref.
(16)]. Indeed, SSc plasma has been shown previously to contain
increased levels of circulating TNFα, platelet microparticles, and
soluble CD40 ligand, which could collaborate in the induction
of TF-1 (38). That TF-1 induction in the setting of exposure
to Zol can be blocked by an anti-TNFα antibody even in the
presence of enhancement by patient’s plasma (Figure 5) sug-
gests that TNFα released by Zol-activated Vγ9δ2+ T cells plays
a major role in induction of TF-1 and that anti-TNFα mAb
could be used to prevent thrombosis in high risk SSc patients
treated with Zol. In addition, our study is the first, to our knowl-
edge, to describe a disease-specific IL-4 response of SSc patients
Vδ1+ T cells to Zol (Figure 1). A bias toward IL-4 secretion by
SSc patients CD4+ TCR αβ T cells in response to non-specific
stimulation has already been observed (39). Moreover, Vδ1+
γδ T cells often predominate in the context of a Th2-biased
environment, e.g., in the broncho-alveolar lavage fluid obtained
from allergic individuals (40, 41). In addition, the majority of
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phosphatidyl-ethanolamine CD1d-restricted γδ T clones in aller-
gic individuals are Vδ1+ and secrete high levels of IL-4 (42). We
hypothesize that Zol stimulation may upregulate co-stimulatory
monocytes CD40, CD80, and CD1d molecules, which in turn,
enhance IL-4 secretion by CD1d-restricted lipid antigen respon-
sive Vδ1+ T cells in the PB of SSc patients (43, 44). The combined
effects of the TNFα secreted by Vγ9δ2 cells, together with the
IL-4 produced by Vδ1+ T cells increases vascular cell adhesion
molecule 1 (VCAM-1) expression on endothelial cells in digital
arteries and VCAM-1-mediated adhesion of TF-1+ monocytes
to the endothelium could then activate local thrombosis and
gangrene (45).
In summary, the hitherto described disastrous consequences of
a seemingly innocuous and highly utilized drug, Zol, in an SSc
patient, which prompted these investigations, led to the discovery
of a novel prothrombotic pathway involving Vγ9δ2 γδ T cells and
CD14+ monocytes and a disease-specific activation of IL-4 pro-
ducing Vδ1 γδ T cells. Future studies into this pathway may lead to
new insights into the immunopathogenic mechanisms of throm-
botic diathesis in immune-mediated, infectious, and malignant
diseases, in which γδ T cells play a role.
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